Skip to main content
. 2022 Jul 28;36(9):2242–2249. doi: 10.1038/s41375-022-01648-4

Fig. 3. Proportion of patients with major molecular response (MMR) based on mutation status at diagnosis.

Fig. 3

Patients carrying an ASXL1 mutation at diagnosis achieved significantly lower MMR probabilities than patients without any mutation, showing 55% (95%-CI: 34–74%) at 12 months (p = 0.0036), 60% (95%-CI: 39–78%) at 18 months (p = 0.0018), and 65% (95%-CI: 43–82%) at 24 months (p = 0.0076). Black vertical lines describe the 95% confidence intervals around the proportions indicated by the upper end of the bars. MMR Major molecular response.